1 to 2% of all urinary lithiasis.
Methods. The SLC3A1 gene sequence was investigated in a Three types of classic cystinuria (I, II, and III) have sample of seven type I/type I, three type I/non-type I, six type been described based on the urinary excretion of cystine I/untyped, and four untyped unrelated cystinuric patients by and dibasic amino acids in obligate heterozygotes [3] RNA single-strand conformation polymorphism (RNA-SSCP).
and on intestinal absorption in homozygotes [1] . Type I Results. Eight new point mutations (S168X, 765ϩ1GϾT, heterozygotes show normal aminoaciduria, whereas type II 766-2AϾG, R452Q, Y461X, S547W, L564F, and C673W) and seven previously reported mutations were detected. These new and III heterozygotes show high or moderate hypermutations increase the number of mutated alleles so far characexcretion of cystine and dibasic amino acids. Type I and terized in SLC3A1 to 62.
II homozygotes show a minimal increase in blood cystine
Conclusions. We have found SLC3A1 mutations in 0.739 of levels after oral loading, whereas type III homozygotes the type I chromosomes studied. The relatively high proportion exhibit a near normal response. Despite these differof uncharacterized type I chromosomes suggests either that there may be mutations not yet found in SLC3A1 or that many ences, the distinction between types II and III is very unof the assigned type I chromosomes in mixed type I/non-type I clear. Therefore, we distinguish two clinical types: (a) patients may have mutations in SLC7A9. If the hypothesis is type I heterozygotes, which present normal aminoacidexcluded in the future, we believe that a third gene may be inuria, and (b) non-type I heterozygotes, which show a varivolved in cystinuria.
able degree of urinary hyperexcretion of cystine and dibasic amino acids [4] . In addition, our linkage data Urinary excretion of cystine, lysine, arginine and ornithine, and the sum of these four amino acids in obligate heterozygotes of type I cystinuria families and in controls, expressed in mol/g of creatinine. Controls are relatives of cystinuria patients with no identified mutations in SLC3A1 or SLC7A9, and non-transmitting cystinuria. These heterozygotes and controls were identified prior to the present study. Data (mean Ϯ SEM) are expressed in mol/g of creatinine in 24-hour urine samples. The 5-95 percentile of each value is given in parenthesis. 'N' denotes the number of individuals.
In 1994, the cystinuria type I gene (SLC3A1) was identiand ornithine (Table 1 ). When at least two parameters (cystine, lysine, or the sum of cystine and dibasic amino fied [6] . In 1997, non-type I cystinuria (types II and III) was linked to a locus on 19q13 [5, 7] . In 1999, SLC7A9, acids) were higher than the maximum value of heterozygotes for mutations in SLC3A1, the proband's relatives the gene causing non-type I cystinuria, was identified [4] .
To date 54 mutations (44 point mutations, 9 large dewere classified as non-type I heterozygotes. Otherwise, they were classified as type I heterozygotes. Seven paletions, and 1 complex mutation) have been described [6, 8- This study describes eight new mutations resulting the phenotypes of patients included in this study is reported in Table 2 . We do not have any information about from a mutational search on a series of seven type I/type I, the stone formation in the patients D3 and B96; all the three type I/non-type I, six type I/untyped, and four remaining but two formed stones in the first one third untyped patients obtained analyzing the whole SLC3A1 decade of life. In addition, the patients P.G., IM93, and coding region, intron/exon boundaries, and 323 nucleo-PR84 underwent the nephrotomy, whereas patient B48 tides of promoter sequence directly on genomic DNA.
had a cystinuric brother affected by renal failure. When The methods of choice were the RNA single-strand con-24-hour urine samples of the proband's parents were not formation polymorphism (RNA-SSCP) technique [22, 23] .
available, we considered urine samples of the proPrevious data on the frequency of 21 different mutaband's children. Urinary amino acid content measuretions in our population indicated that approximately ments, determined by high-pressure liquid chromatogra-0.574 of the overall type I chromosomes were characterphy (HPLC), were corrected per gram of creatinine. ized by mutations in SLC3A1 [11] . In the current study, we report the characterization of 17 out of 23 type I Mutational search chromosomes that account for a proportion of 0.739, and Genomic DNA was isolated from peripheral blood also describe the overall number of SLC3A1 mutations lymphocytes according to standard protocols. DNA amdetected so far in our cystinuric population.
plification by polymerase chain reaction (PCR) was carried out incorporating the T7 phage promoter sequence METHODS in the 5Ј-end of one PCR primer. In this manner, the Patients amplified product can be processed by the RNA-SSCP technique [22, 23] . The primer pairs and the PCR protoTwenty unrelated Italian and Spanish patients were analyzed. Sixteen of them were classified in cystinuria col conditions used to amplify the SLC3A1 exons were those previously described [11] . subtypes on the basis of urinary excretion values of cystine and dibasic amino acids in 24-hour urine specimens
The promoter region was amplified using the primer pairs Dir/5Ј-CTGGGATTACAGGTGCACAC-3Ј (Ϫ343; of their relatives. Four patients who were included in this study remained unclassified because of the impossi-Ϫ324) and Rev/5Ј-TATCTTCAGCCATGTCTCAC-3Ј (13; Ϫ7) under the following conditions: 95ЊC for 5 minbility to recruit their relatives or because the urine analysis was not exhaustive. The criteria for classification were utes, followed by 35 cycles at 94ЊC for 30 seconds, 57ЊC for 30 seconds, and 72ЊC for 30 seconds. To the 5Ј-end based on the excretion levels of known heterozygotes for mutations in SLC3A1 (Table 1) . It is worth menof the forward primer was added a T7 tail, as described previously in this article. The amplification reaction was tioning that the range of the urinary excretion of cystine and the three dibasic amino acids in these SLC3A1 hetperformed using 100 ng of genomic DNA in a total volume of Ϫ25 L, with 5 pmol of each primer and 200 mol/L erozygotes was similar to that of controls, but had a tendency for a higher range in the urine levels of cystine of each dNTP, in PCR buffer containing 1.5 mmol/L The RNA-SSCP protocol has been performed as previously described [9] . Bands showing an electrophoretically altered mobility were then sequenced on a DNA Automatic Sequencer (Applied Biosystems 373A) using the ABI PRISM Dye primer Cycle Sequencing kit according to manufacturer's protocols.
New mutations were also checked by restriction analysis with the enzymes TaqI, MspI, MboI (Promega, Madison, WI, USA), HincII, NcoI (New England BioLabs Inc., Boston, MA, USA), AluI, MaeI, and RsaI (Boehringer Mannheim GmbH), according to manufacturer's instructions. Whenever necessary, a modified primer was designed to construct a restriction site during the PCR (Table 3) .
RESULTS
The whole SLC3A1 coding region, all intron/exon boundaries, some intron sequences (on average 50 bp on each side of the exons), and 323 bp of promoter region were investigated in a sample of 20 Italian and Spanish cystinuric patients. Eight novel mutations were identified: four missense mutations, two nonsense mutations, and two involving a splicing site. We also detected seven previously reported mutations. A summary of the SLC3A1 mutations identified in each cystinuria family is reported in Table 2 , and the novel mutations are listed in Table 3 .
Description of new mutations
Missense mutations. A C to G substitution at nucleotide position 2019 of the gene (exon 10), which changed a cysteine codon (TGC) to a tryptophan (TGG) at position 673 (C673 W), was found in a type I/type I Spanish patient carrying on the other chromosome the 766-2AϾG mutation (discussed later in this article). The C673W mutation could be detected by the restriction site generating-polymerase chain reaction (RG-PCR) method by creating a NcoI restriction site.
The second mutation was a G to A substitution at nucleotide position 1355 (exon 8). The normal codon (CGG), corresponding to arginine residue at position 452, changed to a CAG glutamine codon (R452Q). It was found in one Italian affected chromosome. The mutation could be analyzed by PCR since it created an AluI restriction site.
The third identified mutation was a C to G substitution at nucleotide position 1640 (exon 10). It changes a serine codon (TCG) to a tryptophan (TGG) at position 547 (S547W). It was found in one Italian affected chromosome. Since this substitution created a MboI restriction site, restriction digestion of the PCR fragment was used to confirm the sequence change in the patient.
The fourth mutation identified was a C to T substitu- tion at nucleotide position 1690 (exon 10) that changed a leucine codon (CTC) to a phenylalanine (TTC) at position origin [11] . Also, the mutation M467K described before in an Italian patient from Southern Italy [6] in our study 564 (L564F). It was found in one Italian patient carrying another chromosome, the M467T mutation. The mutawas detected in a patient from the same geographic area. A Northern Italian patient was found to carry the mutation could be analyzed by RG-PCR protocol by destroying a RsaI restriction site.
tion R452W previously described in one American patient [13] . A Spanish patient has been found to carry All missense mutations identified affected residues that were highly conserved in rat, rabbit, and humans [24] [25] [26] .
the mutation R365W previously reported in an Italian patient [9] . Altogether, six subjects were found to be Nonsense mutations. A C to A substitution at nucleotide 503 (exon 2) was detected in one Spanish-affected chroheterozygous for the M467T mutation. A summary of all mutations identified is reported in mosome. This point mutation led to a stop signal (TAG) at position 168 (S168X), and it could be analyzed by the Table 2 . RG-PCR protocol since it destroys a TaqI restriction Survey of the frequency and the occurrence of site. Moreover, subject B78 appeared to be homozygous mutations in our cystinuric population for the observed mutation S168X (data not shown), but further analysis of his relatives allowed us to confirm his
In this study, we identified both mutated alleles in four out of seven type I/type I patients, in three out of six hemizygous status. The characterization of this deletion is in progress.
type I/untyped patients, and in two out of four untyped patients; one mutated allele in two out of seven type The second mutation was a T to G substitution at nucleotide position 1383 (exon 8) that changed a TAT to a I/type I patients, in three out of six type I/untyped patients, in one out of three type I/non-type I patients, and TAG codon, resulting in a nonsense mutation at position 461 (Y461X). It was found in one Italian patient carrying in one out of four untyped patients. Thus, we have characterized 25 out of 40 total chromosomes for SLC3A1 on the other chromosome, the M467T mutation. The mutation could be analyzed by the RG-PCR protocol mutations. Ten out of 14 positive chromosomes were by creating a MaeI restriction site.
found in type I/type I patients accounting for a proporSplicing site mutation. A G to T substitution at nucleotion of 0.714, 1 out of 6 in type I/non-type I patients, 9 tide 765ϩ1 (splice site exon 3/intron 3) was found in two out of 12 in type I/untyped, and 5 out of 8 in untyped Spanish patients. One of them was heterozygous, and patients. If we consider all of the type I chromosomes the other one was homozygous for this point mutation;
from type I/I, type I/non-type I, and type I/untyped pait was possible to confirm the heterozygous state in his tients (17 out of 23), this figure is 0.739. In our cystinuric parents. The substitution destroyed the consensus sepopulation, mutation M467T is the most common allele, quence of splicing site and could be analyzed by the while mutations 163delC, T216M, 765ϩ 1GϾT, R362C, RG-PCR method by creating a HincII restriction site.
R365W, M467K, and E483X were detected at least twice An A to G substitution at nucleotide 766-2 (splice site (Table 4) [6, 9, 11, 12, 16] . intron 3/exon 4) was found in a Spanish patient who carried the C673W mutation on the other chromosome. DISCUSSION The substitution destroyed the consensus site of splicing In this study of 20 cystinuric patients, seven patients site and could be analyzed by PCR since it created a were classified as type I/type I, three as mixed type I/nonMspI restriction site.
type I, and six as type I/untyped; four patients remained None of the described mutations were detected on 86 unclassified because of the impossibility to recruit their normal control chromosomes. A summary of the eight relatives or because the urine analysis was not exhausmutations and primers for the PCR amplification is in tive. The levels of cystine excretion in our patients ranged Table 3 .
from 588 to 5689 mol/g creatinine, and the sum of Previously reported mutations cystine and dibasic amino acids ranged from 2135 to 30250 mol/g creatinine. Five patients formed stones at In addition to the identification of new alleles, we have age one to five years. Eleven formed stones in the second detected seven previously described mutations that charto third decade of life, whereas the patients B48 and acterize 14 chromosomes in our sample. A Spanish pa-DGV103, 43 and 7 years old, respectively, did not form tient was found to be homozygous for the mutation stones. The cystinuria in these patients was diagnosed 163delC [16] , and it was possible to confirm the heterozybecause B48 had a cystinuric brother affected by renal gous state in his parents. A patient of Balkan origin was failure and DGV103 had recurrent episodes of microfound to be homozygous for a T216M mutation first ematuria. In addition, the patients P.G., IM93, and PR84 reported in homozygosity in an Italian gypsy [11] and underwent the nephrotomy. No information about the very frequently appearing in Greek patients [18] . A pastone formation in patients D3 and B96 was available. tient from Southern Italy was found to carry the mutation R362C, previously reported in an individual of the same
The mutational analysis carried out in this group of pa- [6] patient under characterization) the number of different T216M 4 [11] mutated alleles identified so far in the SLC3A1 gene. L564F, C673W) that affect residues highly conserved in S168X 1 this study rat, rabbit, and human rBAT [24] [25] [26] . R181Q 1 [6] Comparing our data with those arising from other tected more than once. This finding combined with the P615T 1 [6] evidence of identification of the same mutations in indi-
1 [6] viduals from identical geographic areas suggests that the C673W 1 this study majority of the mutations in SLC3A1 should be private L678P 1 [6] mutations or/and population specific.
766-2AϾG 1 this study 1749delA 1 [9] In our study, the overall proportion of type I chromo- cystinuria patients. The proportion of type I-positive S420C 0 [16] chromosomes in the present study (0.739) is higher as I445T 0
[20] G458E 0 [16] compared with that reported in our previous studies.
This finding is probably due to the more stringent criteria V536G 0 [16] for classification that is currently used, which now al- there is evidence that in some patients the type I cystinu1306insG 0 [8] ria can be due to mutations in SLC7A9, the gene involved 1500ϩ1 GϾT 0 [12] in determining non-type I cystinuria. Actually, the Span- did not present any mutation in SLC3A1 ( 
